Coronary arteries are the blood vessels that supply blood to the heart. The accumulation of plaques composed of cholesterol and other deposits on the arterial walls can lead to coronary artery stenosis or occlusion, which in turn causes coronary heart disease. Patients may experience symptoms such as angina, palpitations, and shortness of breath. In China, cardiovascular diseases are one of the biggest threats to residents' health. It is estimated that about 330 million people in China are currently suffering from cardiovascular diseases, of which 11.39 million have coronary heart disease. With the acceleration of population aging, the incidence and mortality of coronary heart disease are on the rise, and the number of percutaneous coronary interventions (PCI) for the treatment of coronary heart disease are also increasing.IVUS, as an advanced medical imaging technology, provides doctors with clear imaging of the inside of blood vessels as well as accurate lesion location and measurement information during PCI procedures, becoming the new "gold standard" for coronary artery examination.

Boston Scientific's Intravascular Ultrasound Diagnostic System AVVIGO+ is aMultimodal platform integrating imaging and functional studies,As an IVUS system with artificial intelligence capabilities, the system includes Auxiliary Luminal Assessment (ALA) functionality,Can automatically implement the operation of key steps and provide intuitive, accurate vascular measurement data, significantly reducing operation time. In addition, the system simultaneously integrates the measurement functions of Fractional Flow Reserve (FFR) and Diastolic Flow Ratio (DFR), which can help assess the severity of blockages and stenosis inside the coronary arteries.Provide a basis for decision-making in precision treatment. Meanwhile, the system is equipped with a 7-level quick retraction function and a bedside controller. These innovative features not only make the treatment process for coronary artery disease faster and more efficient but also provide patients with a higher quality treatment experience. According to statistics, compared with the previous generation of intravascular ultrasound diagnostic systems, the new AVVIGO+ system can reduce operation time by 62%.

AVVIGO+ Intravascular Ultrasound Diagnostic System Received FDA Approval in the U.S. and CE Mark in Europe in 2023 and Has Been Clinically Applied.Last month, the system made its "debut" at the 7th China International Import Expo. Just one month later, it completed the transition from "exhibit" to "product," benefiting a wider range of patients and medical professionals in China.